Engineered nanoparticles for imaging and targeted drug delivery in hepatocellular carcinoma

Liver cancer, notably hepatocellular carcinoma (HCC), poses a significant global health burden due to its high fatality rates. Conventional antitumor medications face challenges, including poor targeting, high toxicity, and drug resistance, leading to suboptimal clinical outcomes. This review focused on nanoparticle use in diagnosing and delivering medication for HCC, aiming to advance the development of nanomedicines for improved treatment outcomes. As an emerging frontier science and technology, nanotechnology has shown great potential, especially in precision medicine and personalized treatment. The success of nanosystems is attributable to their smaller size, biocompatibility, selective tumor accumulation, and lower toxicity. Nanoparticles, as a central part of nanotechnology innovation, have emerged in the field of medical diagnostics and therapeutics to overcome the various limitations of conventional chemotherapy, thus offering promising applications for improved selectivity, earlier and more precise diagnosis of cancers, personalized treatment, and overcoming drug resistance. Nanoparticles play a crucial role in drug delivery and imaging of HCC, with the body acting as a delivery system to target and deliver drugs or diagnostic reagents to specific organs or tissues, helping to accurately diagnose and target therapies while minimizing damage to healthy tissues. They protect drugs from early degradation and increase their biological half-life.

Imaging technology in tracking the intravital fate of transplanted stem cells

Stem cell therapy emerges as a promising alternative strategy for diseases that currently lack effective treatment options. Investigating the pharmacokinetic properties of stem cells, such as their survival, migration, differentiation, and engraftment dynamics, offers valuable insights for elucidating therapeutic mechanisms, refining treatment protocols, and ultimately enhancing therapeutic efficacy. Moreover, the pharmaceutical research of stem cell products is an essential prerequisite for regulatory approval. This contribution focus on the development of advanced imaging technologies for noninvasive monitoring the intravital fate of implanted stem cells, as well as the advantages and challenges of each imaging approach. Through comprehensive analysis of stem cell metabolic pathway, we identify critical barriers to clinical translation of stem cell therapy. In the end, we discuss future perspectives and opportunities in stem cell tracking and functional assessment.

Photo-enhanced synergistic sterilization and self-regulated ion release in rGO-Ag nanocomposites under NIR irradiation

Silver ions (Ag+) released from silver nanoparticles (Ag NPs) can help to improve the inhibition and killing ability of particles to bacteria. The leakage of Ag+ ions released from Ag NPs will lead to possible risks in cytotoxicity and environmental damage. It is still a challenge to balance particles' ions release and leakage to environment. Here, a nanocomposite of Ag NPs combined with reduced graphene oxide (rGO), labeled as rGO-Ag, was prepared by laser-induced photoreduction of Ag+ ions in solution. This composite exhibits not only a synergistic effect of Ag NPs and rGO in sterilization under normal circumstances, but also another synergistic effect from photothermal function under the 808 nm near-infrared (NIR) laser irradiation and the subsequent enhanced Ag+ ions release at high temperature. In experiments, rGO works as photothermal converter, which can directly cause the death of bacteria and force Ag+ ions to leave particle surface to assist in killing bacteria, and also as a catcher to intercepts the leakage of the released ions. After treating a 50 mg/L rGO-Ag solution with an NIR laser for 30 min, the concentration of released Ag+ ions increased, but these ions were subsequently adsorbed back onto the rGO. Compared with the no-light treatment group, the mortality rates of E. coli and S. aureus exposed to rGO-Ag under NIR irradiation increased by 39.06 % and 17.48 %, respectively. The clever combination between Ag NPs and rGO makes their composite exhibit a photo-enhanced synergistic sterilizing function, as well as a self-controlled ion release capability under NIR stimulation.

Liquid Biopsy on Microfluidics: From Existing Endogenous to Emerging Exogenous Biomarkers Analysis

Liquid biopsy is an appealing approach for early diagnosis and assessment of treatment efficacy in cancer. Typically, liquid biopsy involves the detection of endogenous biomarkers, including circulating tumor cells (CTCs), extracellular vesicles (EVs), circulating tumor DNA (ctDNA), circulating tumor RNA (ctRNA), and proteins. The levels of these endogenous biomarkers are higher in cancer patients compared to those in healthy individuals. However, the clinical application of liquid biopsy using endogenous biomarker analysis faces challenges due to its low abundance and poor stability in circulation. Recently, a promising strategy involving the engineering of exogenous probes has been developed to overcome these limitations. These exogenous probes are activated within the tumor microenvironment, generating distinct exogenous markers that can be easily distinguished from background biological signals. Alternatively, these exogenous probes can be labeled with intrinsic endogenous biomarkers in vivo and detected in vitro after metabolic processes. In this review, we primarily focus on microfluidic-based liquid biopsy techniques that allow for the transition from analyzing existing endogenous biomarkers to emerging exogenous ones. First, we introduce common endogenous biomarkers, as well as synthetic exogenous ones. Next, we discuss recent advancements in microfluidic-based liquid biopsy techniques for analyzing both existing endogenous and emerging exogenous biomarkers. Lastly, we provide insights into future directions for liquid biopsy on microfluidic systems.

Enhancing nano-immunotherapy of cancer through cGAS-STING pathway modulation

Activation of the cyclic guanosine monophosphate-adenosine monophosphate synthase (cGAS)-stimulator of interferon genes (STING) pathway plays a critical role in cancer immunotherapy due to the secretion of multiple pro-inflammatory cytokines and chemokines. Numerous cGAS-STING agonists have been developed for preclinical and clinical trials in tumor immunity. However, several obstacles, such as agonist molecules requiring multiple doses, rapid degradation and poor targeting, weaken STING activation at the tumor site. The advancement of nanotechnology provides an optimized platform for the clinical application of STING agonists. In this review, we summarize events of cGAS-STING pathway activation, the dilemma of delivering STING agonists, and recent advances in the nano-delivery of cGAS-STING agonist formulations for enhancing tumor immunity. Furthermore, we address the future challenges associated with STING-based therapies and offer insights to guide subsequent clinical applications.

Cell-based immunotherapies for solid tumors: advances, challenges, and future directions

Cell-based immunotherapies, including CAR-T, CAR-NK, and TCR-T therapies, represent a transformative approach to cancer treatment by offering precise targeting of tumor cells. Despite their success in hematologic malignancies, these therapies encounter significant challenges in treating solid tumors, such as antigen heterogeneity, immunosuppressive tumor microenvironments, limited cellular infiltration, off-target toxicity, and difficulties in manufacturing scalability. CAR-T cells have demonstrated exceptional efficacy in blood cancers but face obstacles in solid tumors, whereas CAR-NK cells offer reduced graft-versus-host disease but encounter similar barriers. TCR-T cells expand the range of treatable cancers by targeting intracellular antigens but require meticulous antigen selection to prevent off-target effects. Alternative therapies like TIL, NK, and CIK cells show promise but require further optimization to enhance persistence and overcome immunosuppressive barriers. Manufacturing complexity, high costs, and ensuring safety and efficacy remain critical challenges. Future advancements in gene editing, multi-antigen targeting, synthetic biology, off-the-shelf products, and personalized medicine hold the potential to address these issues and expand the use of cell-based therapies. Continued research and innovation are essential to improving safety, efficacy, and scalability, ultimately leading to better patient outcomes.

Porphyrins and Their Derivatives in Cancer Therapy: Current Advances, Mechanistic Insights, and Prospective Directions

Porphyrin and its derivatives are widely used in cancer therapy due to their strong photon absorption capabilities and moderate light stability. Due to their hydrophobic nature, porphyrins with tetrapyrrolic macrocycles ease self-aggregation in physiological conditions. Instead, exploiting the C4 symmetry structure for self-assembly is beneficial to improve the bioavailability of porphyrin and its derivatives. Herein, this Review outlines porphyrin-based nanoformulations for therapeutic applications in cancer treatment. The typical pharmaceutical application of the integrated porphyrinic structure is systematically summarized, focusing on the typical synthetic methodologies and structure-functionality relationship. Additionally, therapeutic modalities (e.g., photothermal, photodynamic, and sonodynamic) and their synergy mechanism in regulated cell death are overviewed. Special attention is given to emerging technologies in nanocatalytic therapy, therapeutic vaccines, and proteolysis-targeting chimeras, which align with the trend toward personalization and minimal invasiveness in healthcare. Finally, we discuss the challenges and limitations of porphyrinic nanoformulations and explore their future directions in the healthcare sector, aiming to bridge the gap between research and practical clinical application.

Construction of Biomimetic Nanochannel, Property Regulation, and Biomarker Detection

The significance of biomimetic nanochannel in the field of biosensors is gaining increasing recognition. The controllable construction of biomimetic nanochannels and their performance modulation have demonstrated great importance and obtained wide interest. The nanochannels offer high sensitivity, enabling sensors to swiftly identify target biomarkers in complex biological samples, with detection limits reaching the picomolar level. Furthermore, they demonstrate exceptional selectivity and reproducibility, making them ideal tools for biomarker detection. In recent years, biosensors utilizing biomimetic nanochannel have shown remarkable performance in detecting a wide range of biomarkers. This review aims to explore the opportunities and challenges associated with biomimetic nanochannel technology in biosensor applications, focusing on the construction and performance modulation of these nanochannels, as well as their applications in detecting nucleic acids, proteins, organisms, and small molecules. Providing forward-looking insights into this cutting-edge field is aspired, with particular emphasis on technological advancements, addressing current challenges, and discussing future trends.

Neoantigen-based immunotherapy: advancing precision medicine in cancer and glioblastoma treatment through discovery and innovation

Neoantigen-based immunotherapy has emerged as a transformative approach in cancer treatment, offering precision medicine strategies that target tumor-specific antigens derived from genetic, transcriptomic, and proteomic alterations unique to cancer cells. These neoantigens serve as highly specific targets for personalized therapies, promising more effective and tailored treatments. The aim of this article is to explore the advances in neoantigen-based therapies, highlighting successful treatments such as vaccines, tumor-infiltrating lymphocyte (TIL) therapy, T-cell receptor-engineered T cells therapy (TCR-T), and chimeric antigen receptor T cells therapy (CAR-T), particularly in cancer types like glioblastoma (GBM). Advances in technologies such as next-generation sequencing, RNA-based platforms, and CRISPR gene editing have accelerated the identification and validation of neoantigens, moving them closer to clinical application. Despite promising results, challenges such as tumor heterogeneity, immune evasion, and resistance mechanisms persist. The integration of AI-driven tools and multi-omic data has refined neoantigen discovery, while combination therapies are being developed to address issues like immune suppression and scalability. Additionally, the article discusses the ongoing development of personalized immunotherapies targeting tumor mutations, emphasizing the need for continued collaboration between computational and experimental approaches. Ultimately, the integration of cutting-edge technologies in neoantigen research holds the potential to revolutionize cancer care, offering hope for more effective and targeted treatments.

Clinical Translation Challenges and Strategies for Tumour Vaccines Considering Multiple Delivery Routes

BACKGROUND

The high incidence and mortality rates of cancer have kept it at the top of the research agenda for the global healthcare industry, as well as put serious economic pressure on families and society. It has gradually been recognised that reducing the incidence of cancer through various interventions and that combining prevention and treatment are the key to alleviating the burden of cancer.

METHODS

Retrieve and summarize the literature related to the delivery methods of tumor vaccines, and investigate whether these delivery methods have been applied clinically or have been used in clinical trials.

RESULTS

there are a variety of methods for cancer vaccine development, but only a very small number of studies have been able to make strides towards implementing these methods in the clinic, which is closely linked to drawbacks with the means of vaccine delivery.

CONCLUSIONS

This review analyses the reasons why it is difficult to apply these methods in the clinic from the point of view of the delivery method rather than the design of the cancer vaccine. It also describes some of the delivery methods that have not yet been applied for cancer vaccines and, considering this in conjunction with those that are currently used for this purpose, predicts their prospects for future application.

Multifaceted functions of tissue-resident memory T cells in tumorigenesis and cancer immunotherapy

Tissue-resident memory T (TRM) cells are well reported as a strong protective first line of defense against foreign antigens in non-lymphoid tissues. Moreover, TRM cells have demonstrated critical protective roles in antitumor immunity, contributing to enhanced survival and tumor growth inhibition across various cancer types. However, surprisingly, recent studies suggest that TRM cells can exhibit paradoxical effects, potentially promoting tumor progression under certain conditions and leading to adverse outcomes during antitumor immune responses. Understanding the complexities of TRM cell functions will enable us to harness their potential in advancing cancer immunotherapy more effectively. Therefore, this review comprehensively investigates the dual roles of TRM cells in different tumor contexts, highlighting their protective functions in combating cancers and their unfavorable potential to exacerbate tumor development. Additionally, we explore the implications of TRM cell behaviors for future cancer treatment strategies, emphasizing the need for further research to optimize the therapeutic exploitation of TRM cells while mitigating their deleterious effects.

Erythrocyte membrane camouflaged celastrol and bilirubin self-assembly for rheumatoid arthritis immunotherapy based on STING inhibition and RONS clearance

Activation of cGAS-STING signaling pathway and accumulation of reactive oxygen and nitrogen species (RONS) are important issues facing the treatment of rheumatoid arthritis (RA). Here, we report a biomimetic nano-Chinese medicine (HA-RM-Cel-BR) for RA immunotherapy based on STING inhibition of celastrol (Cel) and RONS clearance of bilirubin (BR). HA-RM-Cel-BR is constructed by the carrier-free self-assembly of active ingredients Cel and BR from traditional Chinese medicine, and then camouflaged by hyaluronic acid (HA)-modified red blood cell membranes (RM). HA-RM-Cel-BR prolongs circulation time through RM camouflage, targets inflamed joints by HA modification, and remodels the joint immune microenvironment by STING inhibition and RONS clearance. More importantly, HA-RM-Cel-BR shows excellent therapeutic effects on RA rat model, and significantly reduces hepatotoxicity associated with Cel. Our work provides a new strategy for RA immunotherapy with traditional Chinese medicine ingredients.

Predictive factors and prognostic models for Hepatic arterial infusion chemotherapy in Hepatocellular carcinoma: a comprehensive review

Hepatocellular carcinoma (HCC) is a prevalent and lethal cancer, often diagnosed at advanced stages where traditional treatments such as surgical resection, liver transplantation, and locoregional therapies provide limited benefits. Hepatic arterial infusion chemotherapy (HAIC) has emerged as a promising treatment modality for advanced HCC, enhancing anti-tumor efficacy through targeted drug delivery while minimizing systemic side effects. However, the heterogeneous nature of HCC leads to variable responses to HAIC, highlighting the necessity for reliable predictive indicators to tailor personalized treatment strategies. This review explores the factors influencing HAIC success, including patient demographics, tumor characteristics, biomarkers, genomic profiles, and advanced imaging techniques such as radiomics and deep learning models. Additionally, the synergistic potential of HAIC combined with immunotherapy and molecular targeted therapies is examined, demonstrating improved survival outcomes. Prognostic scoring systems and nomograms that integrate clinical, molecular, and imaging data are discussed as superior tools for individualized prognostication compared to traditional staging systems. Understanding these predictors is essential for optimizing HAIC efficacy and enhancing survival and quality of life for patients with advanced HCC. Future research directions include large-scale prospective studies, integration of multi-omics data, and advancements in artificial intelligence to refine predictive models and further personalize treatment approaches.

Hypoxia-responsive core-cross-linked supramolecular nanoprodrug based on dendritic drug-drug conjugates for synergetic anticancer therapy

BACKGROUND

Recently, the strategy of self-assembling dendritic drug-drug conjugates into supramolecular nanoprodrug was widely explored in biomedical applications. Herein, we construct a hypoxia-responsive core-cross-linked supramolecular nanoprodrug (CSN-IR806/CB) based on a dendritic drug-drug conjugate.

METHODS

We prepared a hypoxia-responsive dendritic drug-drug conjugates IR806-(Azo-CB)4, which was combined with β-cyclodextrin-pendant poly(ethylene glycol)-block-poly(glutamic acid) block copolymer (PEG-PGlu-CD) to construct the core-cross-linked supramolecular nanoprodrug (CSN-IR806/CB) with enhanced physiological stability through the synergy of π-π stacking interaction, host-guest complexation, hydrogen bonds, and hydrophobic interaction.

RESULTS

The near-infrared (NIR) light irradiation of the CSN-IR806/CB treated tumor cells induced IR806-mediated PDT and PTT, and aggravated hypoxia, which triggered the disassembly of CSN-IR806/CB and the subsequent release of activated CB for synergetic cancer cell killing.

CONCLUSIONS

The CSN-IR806/CB can realize a synergistic triple therapeutic effect of photothermal therapy (PTT), photodynamic therapy (PDT), and chemotherapy (CT; i.e., PTT-PDT-CT).

Smart on-demand drug release strategies for cancer combination therapy

In cancer therapy, enhancing therapeutic indices and patient compliance has been a central focus in recent drug delivery technology development. However, achieving a delicate balance between improving anti-tumor efficacy and minimizing toxicity to normal tissues remains a significant challenge. With the advent of smart on-demand drug release strategies, new opportunities have emerged. These strategies represent a promising approach to drug delivery, enabling precise control over the release of therapeutic agents in a programmed and spatiotemporal manner. Recent studies have focused on designing delivery systems capable of releasing multiple therapeutic agents sequentially, while achieving spatial resolution in vivo. Smart on-demand drug release strategies have demonstrated considerable potential in tumor combination therapy for achieving precision drug delivery and controlled release by responding to specific physiological signals or external physical stimuli in the tumor microenvironment. These strategies not only improve tumor targeting and reduce toxicity to healthy tissues but also enable sequential release in combination therapy, allowing multiple drugs to be released in a specific spatiotemporal order to enhance synergistic treatment effects. In this paper, we systematically reviewed the current research progress of smart on-demand drug release drug delivery strategies in anti-tumor combination therapy. We highlighted representative integrated drug delivery systems and discussed the challenges associated with their clinical application. Additionally, potential future research directions are proposed to further advance this promising field.

Direct cell interactions potentially regulate transcriptional programmes that control the responses of high grade serous ovarian cancer patients to therapy

The tumour microenvironment is composed of a complex cellular network involving cancer, stromal and immune cells in dynamic interactions. A large proportion of this network relies on direct physical interactions between cells, which may impact patient responses to clinical therapy. Doublets in scRNA-seq are usually excluded from analysis. However, they may represent directly interacting cells. To decipher the physical interaction landscape in relation to clinical prognosis, we inferred a physical cell-cell interaction (PCI) network from 'biological' doublets in a scRNA-seq dataset of approximately 18,000 cells, obtained from 7 treatment-naive ovarian cancer patients. Focusing on cancer-stromal PCIs, we uncovered molecular interaction networks and transcriptional landscapes that stratified patients in respect to their clinical responses to standard therapy. Good responders featured PCIs involving immune cells interacting with other cell types including cancer cells. Poor responders lacked immune cell interactions, but showed a high enrichment of cancer-stromal PCIs. To explore the molecular differences between cancer-stromal PCIs between responders and non-responders, we identified correlating gene signatures. We constructed ligand-receptor interaction networks and identified associated downstream pathways. The reconstruction of gene regulatory networks and trajectory analysis revealed distinct transcription factor (TF) clusters and gene modules that separated doublet cells by clinical outcomes. Our results indicate (i) that transcriptional changes resulting from PCIs predict the response of ovarian cancer patients to standard therapy, (ii) that immune reactivity of the host against the tumour enhances the efficacy of therapy, and (iii) that cancer-stromal cell interaction can have a dual effect either supporting or inhibiting therapy responses.

IFN-γ/IL-2 Double-Color FluoroSpot Assay for Monitoring Human Primary T Cell Activation: Validation, Inter-Laboratory Comparison, and Recommendations for Clinical Studies

The enzyme-linked immunosorbent spot (EliSpot) assay and its fluorescence-based version, FluoroSpot, are sensitive immunoassays commonly used to quantify antigen-specific T and B lymphocytes and other immune cells in peripheral blood or homogenized tissues. Due to their high sensitivity, these assays are popular in clinical trials to evaluate the efficacy of immunotherapy and vaccines, which involve a high level of scrutiny to ensure valid study results. Besides industry consensus white papers and other research publications, there is no formal guidance for the industry on how to validate EliSpot and FluoroSpot assays to ensure their accurate performance for immune monitoring in clinical trials. Herein, we describe a comprehensive in vitro study using healthy human donor peripheral blood mononuclear cells (PBMCs) and model antigens to validate a double-color FluoroSpot assay for monitoring antigen-specific lymphocytes by detecting and quantifying IFN-γ and IL-2-producing lymphocytes. Validation parameters, acceptance criteria set-up, and assay limits-limit of detection (LOD), minimum positive control response, lower and upper limits of quantification (LLOQ and ULOQ)-were determined, and assay performance was demonstrated by assessing precision, specificity, linearity, and robustness. In addition, an inter-laboratory comparison demonstrated concordance between assay results from two laboratories. In summary, this study outlines a robust approach to EliSpot and FluoroSpot validation and demonstrates that the IFN-γ/IL-2 FluoroSpot assay is suitable for the reliable detection of antigen-specific immune responses from PBMC samples across laboratories and meets the current regulatory requirements for bioanalytical method validation.

Natural product-based nanotechnological formulations for colorectal cancer treatment

Colorectal cancer is one of the most common malignancies affecting the gastrointestinal tract. A silent onset often marks it and carries a poor prognosis. Studies have shown that natural products can suppress the growth of colorectal cancer and exert therapeutic effects at the molecular level. However, unfavorable physicochemical properties frequently hinder their clinical application, such as low solubility, limited bioavailability, short half-life, and rapid systemic clearance. As scientific and technological progress continues, increasing attention has been directed toward nanotechnology-based approaches. Techniques involving nanoparticles, liposomes, and micelles are being explored to improve drug delivery. These advancements provide a promising foundation for overcoming the limitations associated with natural products. This review systematically examines the application of nano-formulations for natural ingredients to offer meaningful insights into their. potential use in treating colorectal cancer.

The miR-941/FOXN4/TGF-β feedback loop induces N2 polarization of neutrophils and enhances tumor progression of lung adenocarcinoma

Background

Lung adenocarcinoma (LUAD) is a major subtype of lung cancer and one of the deadliest cancers in humans. Dysregulation of miRNA activity in tumor-associated neutrophils (TANs) in the tumor microenvironment plays an important role in the occurrence and development of LUAD.

Method

In this study, the miReact algorithm was used to analyze the single-cell RNA sequencing data of LUAD samples to reveal the miRNA profile characteristics of TANs in LUAD patients. The function of miR-941 was investigated in vivo and in vitro. The target gene and underlying signaling pathway of miR-941 were predicted and validated with qPCR, luciferase assay, WB and ELISA assay.

Results

The results indicated the crucial role of TANs, especially N2-TANs in LUAD and miR-941 activity was significantly upregulated in TANs of LUAD patients. MiR-941 overexpression promoted the proliferation, invasion, migration and anti-apoptosis of A549 and H1299. In vivo xenograft mouse model confirmed that miR-941 overexpression enhanced the growth of tumors formed by H1299 cells. Bioinformatics analysis showed that miR-941 targeted the tumor suppressor gene FOXN4, and we confirmed that FOXN4 overexpression could counteract the malignant effects of miR-941. In addition, miR-941 may drive LUAD progression through the FOXN4/TGF-β feedback signaling loop and participate in the N2-TAN polarization.

Conclusion

In summary, these findings reveal the key role of N2-TANs and the miR-941/FOXN4/TGF-β signaling loop in LUAD progression and provide potential therapeutic targets for future interventions.

Advancements in Carbon-Based Piezoelectric Materials: Mechanism, Classification, and Applications in Energy Science

The piezoelectric phenomenon has garnered considerable interest due to its distinctive physical properties associated with the materials involved. Piezoelectric materials, which are inherently non-centrosymmetric, can generate an internal electric field under mechanical stress, enhancing carrier separation and transfer due to electric dipole moments. While inorganic piezoelectric materials are often investigated for their high piezoelectric coefficients, they come with potential drawbacks such as toxicity and high production cost, which hinder their practical applications. Consequently, carbon-based piezoelectric materials have emerged as an alternative to inorganic materials, boasting advantages such as a large specific surface area, high conductivity, flexibility, and eco-friendliness. Research into the applications of carbon-based piezoelectric materials spans environmental remediation, energy conversion, and biomedical treatments, indicating a promising future. This review marks the first comprehensive attempt to discuss and summarize the various types of carbon-based piezoelectric materials. It delves into the underlying mechanisms by which piezoelectricity influences catalysis, biomedical applications, nanogenerators, and sensors. Additionally, various potential techniques are presented to enhance the piezoelectric performance. The design principles of representative fabrication strategies for carbon-based piezoelectric materials are analyzed, emphasizing their current limitations and potential improvements for future development. It is believed that recent advances in carbon-based piezoelectric materials will make a significant impact.

Silver Molybdate Nanoparticles for Enhanced Tumor Immunotherapy through Pyroptosis Conversion and Ferroptosis Induction

Pyroptosis holds great potential in tumor therapy due to its strong immunogenicity. Several strategies, including ion interference therapy (IIT), are developed to induce pyroptosis. However, the mechanism by which metal oxoanions induced pyroptosis remained unclear. It was reported that MoO4 2- ions could stimulate immune responses, but their pyroptosis-inducing mechanisms were not fully understood. Herein, we synthesized uniform and dispersed silver molybdate (Ag2MoO4) nanoparticles (AMO) via a solvothermal method. AMO responded to H2O2 and glutathione (GSH) stimuli, releasing Ag+ and MoO4 2- ions, generating reactive oxygen species (ROS), and depleting GSH, thereby inducing ferroptosis and pyroptosis. The MoO4 2- also inhibited cell migration and upregulated GSDME expression, converting apoptosis into caspase-3/GSDME-mediated pyroptosis. Additionally, DNA damage and ROS activated the cGAS-STING pathway, enhancing innate immunity. In vivo experiments demonstrated that the combination of AMO and the immune checkpoint inhibitor αPD-1 significantly inhibited tumor growth. This combination promoted dendritic cells (DCs) maturation, increased effector T cell numbers, induced M1 macrophage polarization, and alleviated immunosuppression. This study contributed to a deeper understanding of metal oxoanion-mediated pyroptosis, supporting its potential application in cancer immunotherapy.

Phase separation of NELFE modulates chromatin accessibility to promote dichotomous signaling pathways in hepatocellular carcinoma

Biomolecular condensates partition various cellular processes including transcription, DNA repair, and RNA metabolism. We report NELFE, a member of the Negative Elongation Factor complex required for Polymerase II (Pol II) pausing, forms distinct foci mediated by two low complexity sequences. We show NELFE is oncogenic in hepatocellular carcinoma (HCC) by undergoing liquid-liquid phase separation (LLPS) with SMARCB1 to modulate chromatin accessibility to downregulate pro-apoptotic genes through Pol II pausing while activating pro-growth signals to promote HCC progression. Our work highlights the importance of NELFE LLPS as a mechanism of chromatin accessibility to regulate both paused and non-paused genes to drive tumorigenesis in hepatocellular carcinoma.

Diagnostic value of exosome-derived lncRNA PITPNA-AS1 in lung cancer

Background

Lung cancer is one of the most lethal types of cancer, and effective diagnostic biomarkers are required. There is increasing evidences that exosome-secreted lncRNAs could play an important role in lung cancer diagnosis. However, the diagnostic value and molecular mechanism of the key lncRNA PITPNA-AS1 in lung cancer remain unclear.

Methods

qRT-PCR was conducted to determine the levels of exosomal lncRNA PITPNA-AS1 in pleural effusions from lung adenocarcinoma, squamous cell lung carcinoma, and small cell lung cancer patients. Receiver operating characteristic (ROC) curve analyses were used to evaluate the diagnostic accuracy of PITPNA-AS1. Its role in lung cancer development was determined by a series of experiments, including CCK-8, flow cytometry, and transwell assays. RNA pull-down and RNA immunoprecipitation assays were carried out to examine the interaction between PITPNA-AS1 and Fragile X messenger ribonucleoprotein 1 (FMR1).

Results

We discovered PITPNA-AS1 in exosomes from lung cancer patients. Its expression was significantly increased in lung cancer patients compared to non-cancer patients, and it was strongly associated with tumor stage, lymph node metastasis, and distant metastasis in all lung cancer subtypes assessed (all p<0.05). ROC curve analyses demonstrated that exosomal PITPNA-AS1 had a high accuracy for differentiating among lung cancer subtypes. Furthermore, PITPNA-AS1 boosted H1299 and A549 cell proliferation, migration, and invasion. Mechanistically, via direct interaction, PITPNA-AS1 increased FMR1 stability by preventing its ubiquitination.

Conclusions

These results reveal that exosome-derived lncRNA PITPNA-AS1 acts as an oncogene to promote malignant biological behaviors and is a promising diagnostic biomarker in lung cancer.

Self-assembled nano-hybrid composite based on Cu/CuXO nanoflower decorated onto hBNNS for high-performance and ultra-sensitive electrochemical detection of CEA biomarker

Synergistic combination of metal/metal oxide with semiconductor as nano-hybrid composites (NHC), exhibits unmatched potential for developing nano-biosensors with superior stability, sensitivity, and selectivity. In this study, we report the fabrication of hydrothermally synthesized 3D2D NHC based on self-assembled Cu/CuXO-hBNNS for label-free detection of Carcinoembryonic Antigen (CEA). A systematic investigation into the synthesis of CuXO-NF, hBNNS, and Cu/CuXO-hBNNS NHC was carried out using extensive spectroscopic and advanced nanoscale imaging techniques. Uniform deposition of Cu/CuXO-hBNNS films onto pre-hydrolyzed ITO electrodes was achieved at a low DC potential of 15 V using electrophoretic deposition (EPD). Optimum immunoelectrode efficacy was analyzed by monitoring antibody incubation time, electrolyte pH, and control study through FTIR and electrochemical techniques. Electrode study revealed remarkably improved surface chemistry upon Cu/CuXO integration with hBNNS, yielding ∼74 % and ∼ 31 % increase in CV and DPV response along with 3-fold increase in diffusion coefficient compared to bare hBNNS. The sensing response of the BSA/Anti-CEA/Cu/CuXO-hBNNS/ITO nano-biosensor detected CEA concentrations from 0 to 50 ng/mL utilizing [Fe(CN6)3-/4-] as a redox probe and demonstrated an exceptionally low limit of detection of 3.22 pg/mL (R2 = 0.99998). Electrochemical clinical evaluation supported by ELISA test established that Cu/CuXO-hBNNS-based nano-biosensor demonstrates exceptional shelf life, low cross-reactivity, and superior recovery rates in human serum, highlighting its effectiveness for precise and reliable detection.

Integration of single-cell sequencing and mendelian randomization reveals novel causal pathways between monocytes and hepatocellular carcinoma

BACKGROUND

Hepatocellular carcinoma (HCC) represents one of the most prevalent malignant neoplasms worldwide, characterized by poor prognosis and low 5-year survival rates. Despite extensive research, its pathogenesis remains largely unclear. Within the tumor microenvironment (TME), monocytes play a dual role: they participate in tumor cell recognition and elimination while regulating immune responses through cytokine secretion. This study aims to investigate the association between differentially expressed genes in monocytes and HCC development.

METHODS

This investigation employed single-cell transcriptomic analysis of human hepatic innate lymphoid cells (ILCs) to identify monocyte subpopulations and their cellular markers. Subsequently, two-sample Mendelian randomization (MR) analysis was conducted to examine the causal relationships between these cells, their associated genes, and HCC development.

RESULTS

Through comprehensive analysis of the monocyte cluster, we identified 2338 differentially expressed genes (DEGs). MR analysis revealed 13 genes significantly associated with HCC risk: CONCLUSION: This study represents the first integration of single-cell sequencing technology with MR analysis to investigate the relationship between monocytes and HCC. Through this innovative methodological approach, we have revealed potential associations between monocyte gene expression and HCC development, providing new directions for further research on HCC prevention and treatment, as well as identifying potential therapeutic targets.

Current status and recent progress of nanomaterials in transcatheter arterial chemoembolization therapy for hepatocellular carcinoma

Hepatocellular carcinoma (HCC) remains one of the most common cancers worldwide. Transcatheter arterial chemoembolization has become a common treatment modality for some patients with unresectable advanced HCC. Since the introduction of nanomaterials in 1974, their use in various fields has evolved rapidly. In medical applications, nanomaterials can serve as carriers for the delivery of chemotherapeutic drugs to tumour tissues. Additionally, nanomaterials have potential for in vivo tumour imaging. This article covers the properties and uses of several kinds of nanomaterials, focusing on their use in transcatheter arterial chemoembolization for HCC treatment. This paper also discusses the limitations currently associated with the use of nanomaterials.

Leveraging CRISPR-Cas-Enhanced Isothermal Amplification Tools for Quick Identification of Pathogens Causing Livestock Diseases

Prompt and accurate diagnosis of infectious pathogens of livestock origin is of utmost importance for epidemiological surveillance and effective therapeutic strategy formulation. Among various methods, nucleic acid-based detection of pathogens is the most sensitive and specific; but the majority of these assays need expensive equipment and skilled workers. Due to the rapid advancement of clustered regularly interspaced short palindromic repeats-CRISPR-associated protein (CRISPR-Cas)-based nucleic acid detection methods, these are now being widely used for pathogen detection. CRISPR-Cas is a bacterial counterpart of "adaptive immunity", generally used for editing genome. Many CRISPR systems have been modified for nucleic acid detection due to their excellent selectivity in detecting DNA and RNA sequences. The combination of CRISPR with suitable isothermal amplification technologies has made it more sensitive, specific, versatile, and reproducible for the detection of pathogen nucleic acids at the point of care. Amplification of pathogen nucleic acid by isothermal amplification followed by CRISPR-Cas-based detection has several advantages, including short sample-to-answer times and no requirement for laboratory set-up. They are also significantly less expensive than the existing nucleic acid detection methods. This review focuses on the recent trends in the use of this precision diagnostic method for diagnosis of a wide range of animal pathogens with or without zoonotic potential, particularly various isothermal amplification strategies, and visualization methods for sensing bacteria, viruses, and parasites of veterinary and public health importance.

Therapeutic Potential of Local and Systemic Adipose-Derived Mesenchymal Stem Cell Injections in a Rat Model of Experimental Periodontitis: Implications for Cardiac Function

Periodontitis is a common inflammatory disease that not only damages periodontal tissues but also induces systemic effects, including cardiac dysfunction. Mesenchymal stem cells (MSCs) offer regenerative potential due to their ability to differentiate, modulate immune responses, and secrete anti-inflammatory factors. However, the relative efficacy of local versus systemic MSC administration remains unclear. This study evaluated the therapeutic effects of adipose-derived MSCs (AD-MSCs) in a rat model of experimental periodontitis, comparing local and systemic administration. AD-MSCs were characterized based on morphology, surface marker expression, and differentiation potential. Ligature-induced periodontitis was established over 60 days, after which AD-MSCs (1 × 106 cells) were administered either supraperiosteally (local group) or intravenously (systemic group). Periodontal regeneration was assessed through clinical, radiographic, and histopathological analyses, while cardiac function was evaluated using echocardiography and histopathological examinations. Results demonstrated that local AD-MSC administration provided superior therapeutic benefits compared to systemic delivery. Locally administered cells significantly enhanced bone regeneration, reduced inflammation, and improved periodontal tissue architecture. In contrast, systemic administration offered moderate benefits but was less effective in restoring periodontal integrity. Similarly, in the heart, local treatment resulted in greater improvements in systolic function, as indicated by enhanced ejection fraction and fractional shortening, along with reduced myocardial fibrosis. Although systemic administration also provided cardioprotective effects, diastolic dysfunction persisted in both treatment groups. In conclusion, local AD-MSC administration proved more effective in regenerating periodontal tissues and mitigating cardiac dysfunction, highlighting its potential as an optimized therapeutic strategy for periodontitis and its systemic complications.

Mass Spectrometry-Based Proteomics for Next-Generation Precision Oncology

Cancer is the leading cause of death worldwide characterized by patient heterogeneity and complex tumor microenvironment. While the genomics-based testing has transformed modern medicine, the challenge of diverse clinical outcomes highlights unmet needs for precision oncology. As functional molecules regulating cellular processes, proteins hold great promise as biomarkers and drug targets. Mass spectrometry (MS)-based clinical proteomics has illuminated the molecular features of cancers and facilitated discovery of biomarkers or therapeutic targets, paving the way for innovative strategies that enhance the precision of personalized treatment. In this article, we introduced the tools and current achievements of MS-based proteomics, choice of discovery and targeted MS from discovery to validation phases, profiling sensitivity from bulk samples to single-cell level and tissue to liquid biopsy specimens, current regulatory landscape of MS-based protein laboratory-developed tests (LDTs). The challenges, success and future perspectives in translating research MS assay into clinical applications are also discussed. With well-designed validation studies to demonstrate clinical benefits and meet the regulatory requirements for both analytical and clinical performance, the future of MS-based assays is promising with numerous opportunities to improve cancer diagnosis, treatment, and monitoring.

New insights into biomarkers and risk stratification to predict hepatocellular cancer

Hepatocellular carcinoma (HCC) is the third major cause of cancer death worldwide, with more than a doubling of incidence over the past two decades in the United States. Yet, the survival rate remains less than 20%, often due to late diagnosis at advanced stages. Current HCC screening approaches are serum alpha-fetoprotein (AFP) testing and ultrasound (US) of cirrhotic patients. However, these remain suboptimal, particularly in the setting of underlying obesity and metabolic dysfunction-associated steatotic liver disease/steatohepatitis (MASLD/MASH), which are also rising in incidence. Therefore, there is an urgent need for novel biomarkers that can stratify risk and predict early diagnosis of HCC, which is curable. Advances in liver cancer biology, multi-omics technologies, artificial intelligence, and precision algorithms have facilitated the development of promising candidates, with several emerging from completed phase 2 and 3 clinical trials. This review highlights the performance of these novel biomarkers and algorithms from a mechanistic perspective and provides new insight into how pathological processes can be detected through blood-based biomarkers. Through human studies compiled with animal models and mechanistic insight in pathways such as the TGF-β pathway, the biological progression from chronic liver disease to cirrhosis and HCC can be delineated. This integrated approach with new biomarkers merit further validation to refine HCC screening and improve early detection and risk stratification.

Unveiling RNA Editing by ADAR and APOBEC Protein Gene Families

RNA editing is a crucial post-transcriptional modification that alters the transcriptome and proteome and affects many cellular processes, including splicing, microRNA specificity, stability of RNA molecules, and protein structure. Enzymes from the adenosine deaminase acting on RNA (ADAR) and apolipoprotein B mRNA editing catalytic polypeptide-like (APOBEC) protein families mediate RNA editing and can alter a variety of non-coding and coding RNAs, including all regions of mRNA molecules, leading to tumor development and progression. This review provides novel insights into the potential use of RNA editing parameters, such as editing levels, expression of ADAR and APOBEC genes, and specifically edited genes, as biomarkers for cancer progression, distinguishing it from previous studies that focused on isolated aspects of RNA editing mechanisms. The methodological section offers clues to accelerate high-throughput analysis of RNA or DNA sequencing data for the identification of RNA editing events.

The treatment of breast cancer in the era of precision medicine

The management of breast cancer, one of the most common and heterogeneous malignancies, has transformed with the advent of precision medicine. This review explores current developments in genetic profiling, molecular diagnostics, and targeted therapies that have revolutionized breast cancer treatment. Key innovations, such as cyclin-dependent kinases 4/6 (CDK4/6) inhibitors, antibody-drug conjugates (ADCs), and immune checkpoint inhibitors (ICIs), have improved outcomes for hormone receptor-positive (HR+), HER2-positive (HER2+), and triple-negative breast cancer (TNBC) subtypes remarkably. Additionally, emerging treatments, such as PI3K inhibitors, poly (ADP-ribose) polymerase (PARP) inhibitors, and mRNA-based therapies, offer new avenues for targeting specific genetic mutations and improving treatment response, particularly in difficult-to-treat breast cancer subtypes. The integration of liquid biopsy technologies provides a non-invasive approach for real-time monitoring of tumor evolution and treatment response, thus enabling dynamic adjustments to therapy. Molecular imaging and artificial intelligence (AI) are increasingly crucial in enhancing diagnostic precision, personalizing treatment plans, and predicting therapeutic outcomes. As precision medicine continues to evolve, it has the potential to significantly improve survival rates, decrease recurrence, and enhance quality of life for patients with breast cancer. By combining cutting-edge diagnostics, personalized therapies, and emerging treatments, precision medicine can transform breast cancer care by offering more effective, individualized, and less invasive treatment options.

Colorimetric-fluorescent dual-mode background fluorescence-quenching lateral flow immunoassay: Principle, modeling, and application to folic acid detection

Conventional lateral flow immunoassays (LFIAs) face challenges in competitive detection of small molecule antigens, including inverse correlation between signal and analyte concentration and insufficient sensitivity. Background fluorescence quenching lateral flow immunoassay (BF-LFIA) offers a novel solution, but quantitative models to guide quencher design and sensitivity optimization are lacking. This study developed a dual-mode colorimetric-fluorescent BF-LFIA for highly sensitive folic acid (FA) detection using polystyrene-encapsulated ZnS@CdSe quantum dots (QDs) as background fluorophores and gold nanorods (AuNRs) or gold nanoparticles (AuNPs) as quenchers. Based on the inner filter effect (IFE) and heterogeneous capture reaction kinetics, we constructed a mathematical model for this dual-mode BF-LFIA. Under quasi-steady-state approximation, analytical expressions relating FA concentration to colorimetric and fluorescent signals were derived, enabling quantitative description of calibration curves for both modes. Due to higher molar extinction coefficients at excitation and emission wavelengths, AuNRs as quenchers exhibited superior sensitivity compared to AuNPs, achieving limits of detection of 0.14 ng/mL and 0.15 ng/mL for colorimetric and fluorescent modes, respectively. The mathematical model showed good agreement with experimental results. The derived calibration curve equations demonstrated better fitting goodness and residual normal distribution characteristics compared to conventional four-parameter logistic equations. Passing-Bablok regression analysis confirmed good consistency and comparability between the dual-mode BF-LFIA and a commercial FA fluorescent immunoassay kit. This study provides theoretical foundations for understanding dual-mode BF-LFIA principles and guiding optimization, offering new strategies for highly sensitive rapid detection of small molecules and other biomarkers.

Self-Calibrated Stimulated Raman Scattering Spectroscopy for Rapid Cholangiocarcinoma Diagnosis

Cholangiocarcinoma (CCA) is an aggressive malignancy with poor clinical outcomes. The current "gold standard" diagnostic approach, endoscopic retrograde cholangiopancreatography (ERCP)-obtained biopsy, has a relatively low sensitivity (i.e., ∼50%). Here, we developed a bile-based diagnostic system using transient stimulated Raman scattering (T-SRS). Except for the tolerance to autofluorescence inherited from traditional SRS spectroscopy, T-SRS features quantum-limit spectral line shapes and is further improved with self-calibration ability in this research. These advantages make the acquired Raman spectra insensitive to the drifting of the excitation parameters, facilitating long-term reliability. Based on the T-SRS spectra in the C-H stretching region from 76 bile samples accumulated over more than 1 year, we demonstrated high accuracy (i.e., 85 ± 3%) and sensitivity (i.e., 87 ± 9%) for classification between CCA and benign diseases. The T-SRS acquisition only requires ∼9-μL bile samples and features a drastically improved time cost. This study suggests that the self-calibrated T-SRS analysis of the bile sample offers a promising approach for rapid CCA diagnosis.

Neurotrophin-3/chitosan inhibits cuproptosis-related genes to enable functional recovery after spinal cord injury

OBJECTIVES

This study investigated the regulatory mechanisms of cuproptosis-related genes (CRGs) in spinal cord injury (SCI) and explored the therapeutic potential of neurotrophin-3 (NT3)-loaded chitosan in promoting functional recovery.

METHODS

We conducted integrated bulk RNA-seq and single-cell RNA-seq (scRNA-seq) analyses of mouse spinal cord tissue at various time points after SCI. The key CRGs were identified using differential expression analysis, weighted gene co-expression network analysis, and machine learning. The therapeutic effects of NT3-loaded chitosan were evaluated using animal models and molecular docking analysis.

RESULTS

We identified four key CRGs (Atp7a, Cp, Loxl2, and Pde3b) and three key transcription factors (C/EBPα, Stat6, and Runx1) that were upregulated post-SCI, promoting cuproptosis and neuroinflammation. NT3-loaded chitosan treatment significantly inhibited CRG expression and enhanced functional recovery in the animal models. Molecular docking analysis demonstrated binding interactions between chitosan and key CRGs, suggesting a potential mechanism for their therapeutic effects.

CONCLUSIONS

Our findings highlight the critical role of CRGs in SCI progression and the potential of NT3-loaded chitosan as a therapeutic strategy for inhibiting cuproptosis and promoting functional recovery. Future studies should focus on validating these findings in larger cohorts and exploring the detailed mechanisms by which NT3-loaded chitosan modulates CRG expression.

Therapeutic drug monitoring in anti-tuberculosis treatment: a systematic review

BACKGROUND AND OBJECTIVES

The treatment of tuberculosis (TB) depends on anti-TB drugs to eradicate the infection and prevent its transmission. Variability in drug metabolism, interactions, and adherence can affect treatment efficacy. Therapeutic drug monitoring (TDM) is essential for optimizing treatment by adjusting dosages. This systematic review aimed to assess the effectiveness of TDM for anti-TB drugs using different biological matrices and to reveal the techniques employed in TDM.

METHODS

A systematic review included studies reporting anti-TB drug monitoring with relevant analytical methods. Reports were screened to include the type of study, population, countries, sample size, anti-TB drugs, biological matrices, sampling time, and analytical methods.

RESULTS

This systematic review includes 35 articles that focus on methods for quantifying anti-TB drugs in clinical settings through observational studies. The research covers 21 countries, including China, USA, India, Italy, Indonesia, the Republic of Korea, and Germany, and involves diverse populations such as adults, children, and patients with MDR- and XDR-TB, as well as those with HIV co-infection. The studies examine a range of anti-TB drugs, from first-line treatments like isoniazid and rifampicin to second-line options such as bedaquiline and linezolid. Various sampling methods were employed, including human plasma, dried blood spots, urine, hair, and peripheral blood mononuclear cells, with analytical techniques such as LC-MS/MS, HPLC, and UPLC utilized to ensure precise measurement of drug levels.

CONCLUSIONS

The assessment of diverse biological matrices and analytical techniques demonstrates that TDM improves treatment efficacy and safety by individualizing drug dosages. Further research is essential to standardize TDM protocols and investigate novel methodologies to enhance TB treatment outcomes.

Near-Infrared Light-Controlled Nitric Oxide Delivery Combined with In Situ Activated Chemotherapy for Enhanced Multimodal Therapy

Development of nanoplatforms with in situ activation for chemotherapy represents a promising modality for biomedical application. Herein, a multifunctional nanoplatform, CMS@DTC@PDA@RuNO@FA (abbreviated as CDPNF NPs), was developed for highly efficient antitumor therapy, in which diethyldithiocarbamate (DTC)-loaded mesoporous Cu2MoS4 (CMS) nanoparticles were covered by polydopamine (PDA) layers and further covalently modified with a NO donor (RuNO) and a folic acid (FA)-directing moiety. Under the mild acidic tumor microenvironment (TME), the CDPNF NPs co-liberated DTC and Cu2+ in the tumor site, where in situ formation of the highly cytotoxic Cu(DTC)2 complex effectively killed tumor cells. Furthermore, under near-infrared (NIR) light irradiation, the CDPNF NPs could deliver nitric oxide (NO) and produce superoxide anions (O2•-), followed by the formation of more toxic peroxynitrite (ONOO-), which led to promoted cell apoptosis. Under 1064 nm NIR light irradiation, in vivo experiments with CDPNF NPs demonstrated an impressively high tumor inhibition rate (∼97%) while with good biocompatibility. This work represents an in situ activated approach for precision medicine that might imply its promising potential for clinical applications.

Inorganic and hybrid nanomaterials for NIR-II fluorescence imaging-guided therapy of Glioblastoma and perspectives

Glioblastoma (GBM) is the most invasive and lethal brain tumor, with limited therapeutic options due to its highly infiltrative nature, resistance to conventional therapies, and blood-brain barriers. Recent advancements in near-infrared II (NIR-II) fluorescence imaging have facilitated greater tissue penetration, improved resolution, and real-time visualization of GBM, providing a promising approach for precise diagnosis and treatment. The inorganic and hybrid NIR-II fluorescent materials have developed rapidly for NIR-II fluorescence imaging-guided diagnosis and therapy of many diseases, including GBM. Herein, we offer a timely update to explore the contribution of inorganic/hybrid NIR-II fluorescent nanomaterials, such as quantum dots, rare-earth-doped nanoparticles, carbon-based nanomaterials, and metal nanoclusters in imaging-guided treatment for GBM. These nanomaterials provide high photostability, strong fluorescence intensity, and tunable optical properties, allowing for multimodal imaging and enhanced therapeutic efficacy. Additionally, their integration with modern therapeutic strategies, such as photothermal therapy, chemodynamic therapy, photodynamic therapy, sonodynamic therapy, and immunotherapy, has shown significant potential in overcoming the limitations of traditional treatments. Looking forward, future advancements including safe body clearance, long-term biocompatibility, efficient BBB penetration, and extended emission wavelengths beyond 1500 nm could enhance the theranostic outcomes. The integration of dual imaging with immunotherapy and AI-driven strategies will further enhance precision and accelerate the clinical translation of smart theranostic platforms for GBM treatment.

CXCR7 promoted proliferation, migration and invasion in HCC Cells by inactivating Hippo-YAP signaling

BACKGROUND

CXCR7 (ACKR3) has been well-supported as a promoter of growth and metastasis in hepatocellular carcinoma (HCC). Both CXCR7 and Hippo signaling play roles in organ development. We aimed to verify the involvement of Hippo-YAP signaling in CXCR7-regulated HCC proliferation, migration, and invasion.

METHODS

HCCLM3 cells were transfected with si-CXCR7, pcDNA-CXCR7, or related control RNA/empty vector. Cell proliferation was assessed using the Cell Counting Kit-8 (CCK-8), and mRNA and protein levels were measured via quantitative real-time PCR (qPCR) and Western blotting. Colony formation assays were conducted to evaluate proliferation capacity, and Transwell assays were used to assess invasion and migration. Transcriptome data from the TCGA-LIHC dataset were analyzed to investigate the potential effects of CXCR7 in HCC.

RESULTS

si-CXCR7 inhibited cell proliferation in HCCLM3 cells, while pcDNA-CXCR7 promoted it. Migration and invasion were suppressed by si-CXCR7 but enhanced by pcDNA-CXCR7. Patients with higher CXCR7 expression in the TCGA-LIHC dataset had lower overall survival rates and increased gene transcription. The CXCR7-high expressing samples were characterized by the activation of several pathways, including PI3K-AKT signaling, calcium signaling, and the Hippo signaling pathway. si-CXCR7 reduced the relative protein levels of Gαq/11 and GαS while increasing phosphorylated LATS and phosphorylated YAP. Opposite trends in these proteins were observed with pcDNA-CXCR7. Finally, the inhibitory effects of si-CXCR7 on cell proliferation, migration, and invasion were reversed by the YAP inhibitor verteporfin.

CONCLUSION

We suggest that CXCR7 promotes the growth and metastasis of HCC cells, at least in part, by inactivating the Hippo-YAP signaling pathway.

SAP30 promotes clear cell renal cell carcinoma proliferation and inhibits apoptosis through the MT1G axis

Sin3A-associated protein 30 (SAP30) is a crucial component of the SIN/HDAC histone deacetylase complex and acts as a scaffold that facilitates target gene binding. SAP30 is highly expressed in various tumours; however, its role in renal cell carcinoma (RCC) remains unclear. In our study, we observed the upregulation of SAP30 in clear cell renal cell carcinoma (ccRCC) tissues, and its elevated expression was correlated with a poor prognosis. Previous research has suggested that SAP30 may influence the growth, proliferation, and apoptosis of RCC cells. Gene Ontology (GO) analysis of the downstream regulatory targets of SAP30 revealed that SAP30 suppressed the expression of MT1G, a protein that binds to p53. Mechanistically, SAP30 inhibited MT1G transcription, thereby impairing the function of MT1G in delivering zinc ions to p53, which diminished p53 activity. Moreover, reduced MT1G levels attenuated the inhibitory effect of MT1G on MDM2, further destabilizing p53. Consequently, this cascade promoted RCC progression. In conclusion, our findings indicate that SAP30 inhibits the p53 pathway through MT1G suppression, suggesting that SAP30 and MT1G are potential prognostic markers and therapeutic targets for RCC.

ATG9B-4 accelerates the proliferation and migration of liver cancer cells in an ARNTL-CDK5 pathway-dependent manner: A case-control study

Lnc ATG9B-4 aggravated the progression of liver cancer by up-regulating cyclin-dependent-kinase 5 (CDK5). It could be inferred that ATG9B-4 indirectly regulates the expression of CDK5 via lncRNA-mediated negative regulation of target genes. Therefore, the specific molecular mechanism by which ATG9B-4 regulates the malignant characteristics of liver cancer cells still needs further study. The differentially expressed genes were identified by mRNA sequencing in liver cancer cells transfected with or without ATG9B-4. Liver cancer cells were transfected with ATG9B-4, ARNTL, or si-CDK5. The expression of aryl basic helix-loop-helix ARNT like 1 (BMAL1, also known as ARNTL), CDK5, and ATG9B-4 was analyzed by real-time quantitative PCR and western blotting. The proliferation and invasion of the transfected cells were respectively analyzed by cell counting kit-8 and wound healing assays, respectively. The ARNTL expression was down-regulated in the liver cancer tissues and liver cancer cells transfected with ATG9B-4. Low ARNTL expression indicated poor overall survival in patients with liver cancer. The optical density of cells transfected with ATG9B-4 and ARNTL was significantly lower than that of cells transfected with ATG9B-4. The wound areas of cells transfected with ATG9B-4 and ARNTL were markedly wider than those of cells transfected with ATG9B-4. The expression of CDK5 was down-regulated in cells transfected with ARNTL. CDK5 knockdown partially attenuated the ATG9B-4-induced increase in proliferation and migration in liver cancer cells. ATG9B-4 deteriorated the proliferation and migration of liver cancer cells in an ARNTL-CDK5 pathway-dependent manner.

Discovery of Genomic Targets and Therapeutic Candidates for Liver Cancer Using Single-Cell RNA Sequencing and Molecular Docking

Liver cancer is one of the most common malignancies and the second leading cause of cancer-related deaths worldwide, particularly in developing countries, where it poses a significant financial burden. Early detection and timely treatment remain challenging due to the complex mechanisms underlying the initiation and progression of liver cancer. This study aims to uncover key genomic features, analyze their functional roles, and propose potential therapeutic drugs identified through molecular docking, utilizing single-cell RNA sequencing (scRNA-seq) data from liver cancer studies. We applied two advanced hybrid methods known for their robust identification of differentially expressed genes (DEGs) regardless of sample size, along with four top-performing individual methods. These approaches were used to analyze four scRNA-seq datasets, leading to the identification of essential DEGs. Through a protein-protein-interaction (PPI) network, we identified 25 hub-of-hub genes (hHubGs) and 20 additional hHubGs from two naturally occurring gene clusters, ultimately validating a total of 36 hHubGs. Functional, pathway, and survival analyses revealed that these hHubGs are strongly linked to liver cancer. Based on molecular docking and binding-affinity scores with 36 receptor proteins, we proposed 10 potential therapeutic drugs, which we selected from a pool of 300 cancer meta-drugs. The choice of these drugs was further validated using 14 top-ranked published receptor proteins from a set of 42. The proposed candidates include Adozelesin, Tivozanib, NVP-BHG712, Nilotinib, Entrectinib, Irinotecan, Ponatinib, and YM201636. This study provides critical insights into the genomic landscape of liver cancer and identifies promising therapeutic candidates, serving as a valuable resource for advancing liver cancer research and treatment strategies.

A dual-responsive ratiometric fluorescent probe for the detection of hypochlorite and hydrazine in environmental samples, live cells, and plant tissues

Hypochlorite (ClO-), a potent oxidizer and disinfectant, and hydrazine, a powerful reducing agent, are widely used in daily life and various industries. However, their extensive use comes with significant risks, as they are highly toxic to both the environment and human health. They have been associated with various health issues and even linked to cancer. Therefore, the simultaneous detection of hypochlorite and hydrazine is crucial for assessing their impact and monitoring the onset and progression of related diseases. A phenanthroimidazole-indandione based colorimetric and ratiometric fluorescent probe PIID was designed and synthesized for dual channel detection of hypochlorite and hydrazine in environmental and biological samples. Probe PIID, which showed a strong yellow-orange emission at 640 nm with a massive Stokes shift of 220 nm, exhibited excellent fluorescence change from yellow-orange to green (526 nm) in the presence of ClO- and from yellow-orange to blue (424 nm) in the presence of hydrazine in an aqueous-THF solvent system. A strong ICT effect, which was acting in probe PIID, gets weakened through ClO- - mediated cleavage of the CC bridge bond to produce aldehyde PIB with a blue shift of 114 nm and hydrazine-induced hydrazinolysis of the indanedione moiety to form hydrazone compound PIBH with a blue shift of 216 nm and that was also confirmed by DFT studies. Not only that, the probe exhibits excellent selectivity over other ROS (reactive oxygen species) and amines with a very fast response time of 40 seconds for hypochlorite and 90 seconds for hydrazine, and high sensitivity was observed with detection limits of 32.75 nM for hypochlorite and 92 nM for hydrazine. Moreover, PIID was employed to monitor both the analytes successfully in environmental water samples and in a solid-state TLC strip study. Hypochlorite was monitored in commercial disinfectants, and by exogenous bioimaging in human breast cancer cells (MDA-MB 231) and endogenous bioimaging in RAW 264.7 macrophage cells with very low cytotoxicity and good cell viability. Meanwhile, hydrazine was tracked in soil samples, and confocal imaging was performed on onion tissue.

Biomechanics-based Gradient Nano-surface Implants Screening and Its Adoption in Dental Implant Repair

BACKGROUND

this study aimed to screen the micro/nano surface of pure titanium implant gradient for performance analysis, and to explore its role in dental implant repair.

METHODS

after treatment with different concentrations of hydrofluoric acid and varying etching times, titanium plates with micro/nano gradient surfaces were selected and divided into four groups: polished, b, c, and d. The microscopic morphology of the titanium surfaces was observed, and the contact angle was measured. One implant was inserted into the femoral metaphysis on both sides of 28 SD rats. Histological sections were analyzed, and the maximum pull-out force was measured.

RESULTS

the new bone trabeculae on the surfaces of groups b, c, and d were wider as against polished group. The surface morphology of the titanium disks etched with 1.2 % hydrofluoric acid for 15 min (group d) was more uniform, the diameter of micropores was the largest, and the contact angle was the smallest (12.1 ± 1.17°). The new bone structure on the surface of implant screws in group d was slightly higher as against groups b and c. The bone-to-implant contact (BIC) and the maximum pullout force in groups b (33.25±2.57 %, 58.52±4.03 N), c (35.16±2.35 %, 59.43±3.97 N), d (40.93±2.71 %, 68.22±4.36 N) were higher as against polished group (22.41±2.86 %, 30.12±4.71 N) (P < 0.05). Three months after implantation, the bone fusion rate in the other three groups was significantly higher than that in the polishing group, with group d showing higher rates compared to groups b and c (P < 0.05).

CONCLUSION

the gradient micro/nano surface was constructed by hydrofluoric acid. The osseointegration of hydrofluoric acid etching implant surface and implant was clearly better as against polished group.

Co-Encapsulation of Multiple Antineoplastic Agents in Liposomes by Exploring Microfluidics

The inherent complexity of cancer proliferation and malignancy cannot be addressed by the conventional approach of relying on high doses of a single powerful anticancer agent, which is associated with poor efficacy, higher toxicity, and the development of drug resistance. Multiple drug therapy (MDT) rationally designed to target tumor heterogeneity, block alternative survival pathways, modulate the tumor microenvironment, and reduce toxicities would be a viable solution against cancer. Liposomes are the most suitable carrier for anticancer MDT due to their ability to encapsulate both hydrophilic and hydrophobic agents, biocompatibility, and controlled release properties; however, an adequate manufacturing method is important for effective co-encapsulation. Microfluidics involves the manipulation of fluids at the microscale for the controlled synthesis of liposomes with desirable properties. This work critically reviews the use of microfluidics for the synthesis of anticancer MDT liposomes. MDT success not only relies on the identification of synergistic dose combinations of the anticancer modalities but also warrants the loading of multiple therapeutic entities within liposomes in optimal ratios, the protection of the drugs by the nanocarrier during systemic circulation, and the synchronous release at the target site in the same pattern as confirmed in preliminary efficacy studies. Prospects have been identified for the bench-to-bedside translation of anticancer MDT liposomes using microfluidics.

A Versatile Strategy to Transform Cationic Polymers for Efficient and Organ-Selective mRNA Delivery

The progress of mRNA therapeutics underscores the imperative demand for the development of targeted delivery systems. While cationic polymers hold promise as genetic vectors, their poor in vivo efficacy and numerous variants highlight the urgent need for a universal functionalization strategy to bolster their delivery capabilities. Here, we present a versatile strategy to transform low-cost commercial cationic polymers into phospholipidated and alkylated polymers (PAPs), enabling efficient and organ-selective mRNA delivery in vivo. This straightforward post-functionalization method can be readily broadened to a diverse array of existing cationic polymers, enhancing their cellular uptake, endosomal escape, and mRNA release functionalities. Consequently, PAPs facilitate up to 30,500-fold higher mRNA expression compared to their unmodified counterparts in vivo. Notably, the one-component PAPs enable spleen-specific mRNA delivery, with their vaccine application validated in a mouse melanoma model following intravenous administration. Better still, PAPs can synergize with different helper lipids to formulate four-component lipid nanoparticles (LNPs), achieving respective lung- and liver-specific mRNA delivery. Noteworthy is that these organ-selective mRNA delivery systems significantly outperform previous polymer and LNP benchmarks. This transformation strategy for cationic polymers represents a generalized methodology to give highly effective mRNA carriers, highlighting substantial potential for clinical translation of mRNA therapies with organ-targeting requirements.

A Fast Immunosensor Based on Biohybrid Self-Assembled Nanostructures for the Detection of KYNA as a Cerebrospinal Fluid Biomarker for Alzehimer's Disease

Although the role of kynurenic acid (KYNA) is not yet fully understood, recent research has implicated this tryptophan (Trp) metabolite as a significant biomarker in neurodegenerative diseases. In this study, we developed an immunosensor platform based on self-assembled polyelectrolyte multilayers (PEMs), employing an enzyme-labeled immunoreagent in a competitive displacement format that requires only a single wash step. This immunosensor enables the detection of KYNA and Trp with detection limits (LOD) of 9 pg/mL and 1.2 ng/mL, respectively. Results validated by traditional ELISA methods indicated elevated levels of KYNA and an increased KYNA/Trp ratio in the cerebrospinal fluid (CSF) of Alzheimer's patients compared to controls, consistent with previous findings. Additionally, this immunosensor platform can be readily adapted to detect other neuroactive Trp metabolites by substituting specific immunoreagents, supporting a flexible profile-based approach. This platform could serve as a rapid, cost-effective clinical tool for monitoring neurological and psychiatric disorders, potentially advancing therapeutic strategy development.

A Nano-Strategy for Advanced Triple-Negative Breast Cancer Therapy by Regulating Intratumoral Microbiota

Intratumoral microbiota have been identified as a component of the tumor microenvironment that regulates the metastatic behavior of tumors. They serve not only as indicators of tumor pathology but also as potential drug targets in cancer therapy. Herein, a multifunctional nanoplatform (DD@FEL) is prepared by combining antibiotic doxycycline (DOXY) that can combat intratumoral microbiota and the chemotherapeutic drug doxorubicin (DOX) in ergosterol-originated liposome. Specially, ergosterol is utilized as a substitute for cholesterol in liposomes to exert pharmacological activity. Mechanistically, DD@FEL leveraged DOXY to inhibit cancer metastasis based on the regulation of intratumoral microbiota, which synergizes with the chemotherapeutic effect of DOX, eventually inhibiting the progression of triple-negative breast cancer (TNBC). Verified both in vitro and in vivo, DD@FEL effectively exerts a cytotoxic effect on TNBC cells, delays the growth of primary TNBC, and attenuates the development of its lung metastasis, providing a promising therapeutic strategy to control both orthotopic and metastatic TNBC.

Optimization of seebeck coefficients in polyaniline-doped manganese dioxide nanocomposites

Polyaniline (PANI) and PANI-MnO2 composites were synthesized via a chemical route with varying manganese dioxide (MnO2) content, specifically 5wt% and 15wt%. X-ray diffraction (XRD) confirmed the structural formation of both PANI and PANI-MnO2 composites. The direct current conductivity was measured, showing an increase with temperature: at 393K, pure PANI had a conductivity of 2.25 × 10-4 S/cm, which increased significantly in the composites, reaching 9.03 × 10-4 S/cm for the 15wt% MnO2 composite. The Seebeck coefficient also increased with temperature and MnO2 concentration, achieving a maximum value of 52 mV K-1 at 373K for the 15wt% MnO2 composite. These results indicate that the synthesized PANI- MnO2 composites exhibit semiconducting behavior with improved thermoelectric properties, making them promising candidates for applications in thermoelectric devices such as generators and thermopiles. The study highlights the potential of these materials in enhancing the efficiency of thermoelectric energy conversion.

A review on the advancement of polydopamine (PDA)-based nanomaterials for cancer treatment

The significance of cancer treatment research lies in addressing the high incidence of cancer, overcoming treatment challenges, and mitigating the harsh side effects of chemotherapeutic agents. Currently, nanotechnology is garnering significant attention for its potential applications in diagnostics and drug delivery, offering innovative solutions for disease detection and treatment. Among different types of nanoparticles (NPs), polymeric nanoparticles comprise biocompatible and biodegradable polymers that enhance drug pharmacokinetics and pharmacodynamics, minimize adverse effects, increase stability, and facilitate sustained drug release. These polymeric nanoparticle-based nanomedicines offer a versatile platform for various cancer treatments, notably enabling targeted drug delivery directly to tumors, tumor-imaging, hyperthermia, and photodynamic therapy. Being polymeric in nature polydopamine (PDA) nanomaterials are appeared as promising approaches in biology and medicine. This review article offers a concise summary of the latest developments in polydopamine-based cancer treatment, covering key findings, limitations, and emerging trend therapeutic approach of polydopamine nanomaterials, along with the properties and various methods of preparation. Physico-chemical properties of PDA-based nanomaterials in therapeutics have permitted several successful modifications in the field of cancer treatment.